NVO – Oversold Setup Showing Signs of Bottoming Amid Healthcare Rebound

After months of steady decline, NVO appears to be stabilizing just as the broader healthcare sector — led by a surge in Eli Lilly (LLY) — is regaining momentum. The sector rotation back into large-cap pharma and biotech has been strong over the past few weeks, and NVO could be positioned to benefit from that shift. Call flow has been coming in as well over the past couple of weeks.

The Technical Picture

On the weekly chart, NVO has pulled back sharply from its 2023 high near $148, bottoming out around $45 — roughly where it launched its last major uptrend two years ago. That area coincides with a high-volume node on the profile and prior breakout support. The MACD, which has been buried in negative territory for months, is finally curling upward, suggesting that bearish momentum is fading.

The 50-week moving average sits above at $69.72, with key resistance zones around $83 and $95. A move through $55–57 would mark a confirmed higher low and could open the door to a sustained rally toward those upper levels.

On the Daily Chart

The stock recently reclaimed short-term moving averages after spending months under pressure. The MACD crossover has turned positive for the first time since spring, and the recent increase in volume on up days hints at early accumulation.

In the context of LLY’s breakout and broad strength in healthcare, this improving structure on NVO looks timely. Institutional money rotating back into the sector could provide additional tailwinds, especially for high-quality names that have already been heavily discounted.

The Trade

I entered a starter call position on November 11th, looking for continuation toward the $60–65 area as the next resistance zone. My risk is defined below $45, the recent low and long-term support.

Disclaimer: This post is for informational and educational purposes only. Nothing here should be considered financial advice or a recommendation to buy or sell any security. Always do your own research and trade based on your own risk tolerance and strategy.